Auristone
Singapore, Singapore· Est.
Epigenomics‑driven cancer diagnostics and services focused on Asian populations.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $5M
AI Company Overview
Epigenomics‑driven cancer diagnostics and services focused on Asian populations.
Oncology
Technology Platform
Proprietary histone‑modification profiling via ChIP‑Seq combined with RNA‑Seq to generate actionable epigenomic insights that complement genomic data.
Opportunities
Expansion of EPI‑CALL™ into broader Asian markets and integration with genomics partners; leveraging the Asian epigenomic database for drug‑discovery collaborations and biomarker licensing.
Risk Factors
Regulatory hurdles for clinical test adoption, dependence on high‑throughput NGS infrastructure, and competition from larger genomics‑diagnostic firms expanding into epigenomics.
Competitive Landscape
Key competitors include Illumina’s TruSight Epigenetics, Guardant Health, and other NGS‑based diagnostic firms; Auristone differentiates through its focus on histone‑modification profiling and a curated Asian epigenomic reference database.